Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670440 | 0.87 | HRH3 (0.55) | HRH3KCNH2 | |
| SCHEMBL4670693 | 0.82 | HRH3 (0.58) | HRH3KCNH2 | |
| SCHEMBL4670313 | 0.81 | HRH3 (0.57) | HRH3KCNH2 | |
| SCHEMBL3577507 | 0.81 | HRH3 (0.54) | HRH3 | |
| SCHEMBL4670659 | 0.80 | HRH3 (0.53) | NAMPTHRH3 | |
| SCHEMBL4670386 | 0.79 | HRH3 (0.50) | NAMPTHRH3KCNH2 | |
| SCHEMBL4672783 | 0.79 | HRH3 (0.63) | HRH3 | |
| SCHEMBL4673152 | 0.78 | HRH3 (0.60) | NAMPTHRH3KCNH2 | |
| SCHEMBL4672740 | 0.76 | HRH3 (0.51) | HRH3KCNH2 | |
| SCHEMBL4670675 | 0.76 | HRH3 (0.50) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1610786-B9 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | EP | claimed |
| EP-1610786-B1 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2007-06-20 | — | — | EP | claimed |
| US-20060205774-A1 | 4-(4-(Heterocyclylakoxy) phenyl-1-(heterocyclyl-carbonyl) piperidine derivavites and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | US | claimed |
| EP-1610786-B9 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| EP-1610786-B1 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205774-A1 | 4-(4-(Heterocyclylakoxy) phenyl-1-(heterocyclyl-carbonyl) piperidine derivavites and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's | HRH3, HRH4, HRH1 | NAMPT 1994/4885HRH3 1/4885KCNH2 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.